News
Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 with Venetoclax December 09, 2024 06:00 AM Eastern Standard Time ...
Enrollment of patients is progressing smoothly into the Phase I portion of the Phase I/II study of DFP-10917 combined with Venetoclax in AML patients previously treated with Venetoclax, one regimen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback